NCT04325672View on ClinicalTrials.gov

Convalescent Plasma to Limit Coronavirus Associated Complications

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 1, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
Coronavirus
Interventions
BIOLOGICAL

Convalescent Plasma

Anti-SARS-CoV-2 convalescent plasma obtained from patients identified as having recovered from COVID-19 with neutralizing antibody titers \>1:64.

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04325672 - Convalescent Plasma to Limit Coronavirus Associated Complications | Biotech Hunter | Biotech Hunter